| Title |
A phase II study of combination therapy with oral S-1 and cisplatin in elderly patients with advanced gastric cancer
|
|---|---|
| Published in |
Gastric Cancer, August 2017
|
| DOI | 10.1007/s10120-017-0753-2 |
| Pubmed ID | |
| Authors |
Yusuke Sasaki, Satoru Iwasa, Shunsuke Okazaki, Masahiro Goto, Yasushi Kojima, Atsushi Naganuma, Kengo Nagashima, Yushi Nagai, Hidekazu Hirano, Yoshitaka Honma, Atsuo Takashima, Ken Kato, Tetsuya Hamaguchi |
| Abstract |
A combination of S-1 and cisplatin is recognized as one of the standard first-line chemotherapy regimens for patients with advanced gastric cancer. However, demographic analyses of pivotal phase III studies have showed that only a minority of treated patients were aged 76 years or older. The purpose of this phase II study was to evaluate the safety and efficacy of combination therapy with S-1 and cisplatin in elderly patients with chemotherapy-naive advanced gastric cancer. Patients aged 76 years or older received S-1 40 mg/m(2) orally twice daily for 21 days and cisplatin 60 mg/m(2) intravenously infused at day 8 of each 35-day cycle. Dose modification was performed according to creatinine clearance. The primary endpoint was overall survival (OS). Secondary endpoints included response rate, progression-free survival (PFS), time to treatment failure (TTF), and adverse events. A total of 40 patients were enrolled. Median OS was 12.3 months, PFS was 7.8 months, and TTF was 4.3 months. The response rate was 54%. The most common grade 3-4 adverse events were anorexia (25%), neutropenia (23%), hyponatremia (20%), anemia (18%), and febrile neutropenia (8%). No treatment-related death occurred. Combination chemotherapy with S-1 and cisplatin is an effective and well-tolerated regimen for elderly patients with advanced gastric cancer when the dose is adjusted according to renal function. |
Mendeley readers
The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 26 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 15% |
| Other | 3 | 12% |
| Student > Ph. D. Student | 3 | 12% |
| Lecturer | 2 | 8% |
| Student > Bachelor | 2 | 8% |
| Other | 4 | 15% |
| Unknown | 8 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 35% |
| Biochemistry, Genetics and Molecular Biology | 2 | 8% |
| Sports and Recreations | 2 | 8% |
| Nursing and Health Professions | 1 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Other | 2 | 8% |
| Unknown | 9 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 August 2017.
All research outputs
#20,441,465
of 22,996,001 outputs
Outputs from Gastric Cancer
#468
of 602 outputs
Outputs of similar age
#276,934
of 317,441 outputs
Outputs of similar age from Gastric Cancer
#8
of 12 outputs
Altmetric has tracked 22,996,001 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 602 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,441 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.